ライフサイエンスコーパス: diphtheria

1 orynebacterium diphtheriae cause respiratory diphtheria.

2 ed to assist clinicians in managing clinical diphtheria.

3 vaccines have prevented 40 million cases of diphtheria, 35 million cases of measles, and a total of

4 tussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertussis/inactivated-p

5 The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine booster b

6 Tdap (adolescent and adult tetanus, reduced diphtheria, acellular pertussis) vaccine.

7 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular pertussis (Tdap) immunization in pr

8 ality in high-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines in their

9 ed the vaccine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preven

10 Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons

11 012, the scheduled administration of tetanus/diphtheria/acellular pertussis and meningococcal vaccine

12 Antibodies to diphtheria and some CRM-conjugated antigens were also lo

13 in an original safety study of a combination diphtheria and tetanus toxoids and acellular pertussis a

14 nological and gestational age and receipt of diphtheria and tetanus toxoids and acellular pertussis v

15 enty-five subjects received a single dose of diphtheria and tetanus toxoids and acellular pertussis v

16 ildhood and adolescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis,

17 ildhood and adolescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis,

18 ne children (78%) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the tim

19 ntrations of PFASs and of antibodies against diphtheria and tetanus were measured and were compared w

20 er delivery in women immunized with tetanus, diphtheria, and acellular pertussis (Tdap) after the 20t

21 women are recommended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at 27

22 Women are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at th

23 ion Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for p

24 ountries have recommended universal tetanus, diphtheria, and acellular pertussis immunisation during

25 ernal vaccination with tetanus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) could

26 ial tetanus-diphtheria booster with tetanus, diphtheria, and acellular pertussis vaccine for adolesce

27 coccal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertussis vaccines.

28 Thirty infants of Tdap (tetanus, diphtheria, and acellular pertussis)-vaccinated pregnant

29 posure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles and rubella

30 GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and 1 month postprimary (D127) and postboost

31 easonal influenza; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertu

32 rotective level of 0.1 IU/mL for tetanus and diphtheria antibodies at age 7 years.

33 erence of -39% (95% CI, -55% to -17%) in the diphtheria antibody concentration.

34 xposure at 7 y was associated with losses in diphtheria antibody concentrations at 13 y of 10-30% for

35 Diphtheria antibody concentrations decreased at elevated

36 Diphtheria antitoxin (DAT) has been the cornerstone of t

37 Diphtheria antitoxin was issued in two (9.5%) cases; bot

38 e population was seropositive to tetanus and diphtheria as defined by a protective serum antibody tit

39 >/=95% of infants were seroprotected against diphtheria at D127 and >/=91% of infants had seroprotect

40 vaccination (eg, replacing decennial tetanus-diphtheria booster with tetanus, diphtheria, and acellul

41 escribe the case of a patient with cutaneous diphtheria caused by toxigenic Corynebacterium ulcerans

42 Scd3-Cre-induced, diphtheria chain A toxin-mediated depletion of sebaceous

43 compared to the prior 12 months for tetanus diphtheria combination, 23-valent pneumococcal polysacch

44 port on the effect of adding a pertussis and diphtheria component to the tetanus vaccination program

45 We previously reported that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccin

46 on will remain protected against tetanus and diphtheria for >/=30 years without requiring further boo

47 receiving host Treg depletion with the IL-2-diphtheria fusion protein (IL2DT), the rate was 27%, wit

48 Although the global incidence of diphtheria has declined steadily over the last quarter o

49 attack rate ratio analysis of the decline of diphtheria in Baltimore (1936), and a 1936 lecture on th

50 ic Corynebacterium diphtheriae strains cause diphtheria in humans.

51 h C. diphtheriae isolates that dominated the diphtheria outbreak in the former Soviet Union in the 19

52 y she had received four vaccinations against diphtheria, pertussis and tetanus, which contained gelat

53 ith receipt of the first and second doses of diphtheria, pertussis, and tetanus vaccine (ie, 6 and 10

54 hildren immunized with the third dose of the diphtheria-pertussis-tetanus vaccine (DPT3) and those wh

55 hat administrative coverage with 3rd dose of diphtheria-pertussis-tetanus vaccine in the 107 high-ris

56 n, infants were reached with a third dose of diphtheria-pertussis-tetanus vaccine, achieving 51% cove

57 ad been delivered during the CHDs instead of diphtheria-pertussis-tetanus vaccine, an additional 5000

58 childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and maternal tetanu

59 te ablation of myeloid cells using the human diphtheria receptor system (diphtheria toxin receptor [D

60 idelines for the public health management of diphtheria, released as final guidelines in March, 2015.

61 were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively.

62 t adult vaccination schedule for tetanus and diphtheria should be revisited.

63 soma cruzi, and bacterial infections such as diphtheria still contribute to the global burden of the

64 survey of current diagnostic techniques for diphtheria surveillance conducted across the European Un

65 The European Diphtheria Surveillance Network (EDSN) ensures the relia

66 with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lym

67 5 years who received the Tdap or tetanus and diphtheria (Td) vaccine during 1 January 2006-31 Decembe

68 ountries improved coverage in three doses of diphtheria tetanus pertussis containing vaccine between

69 phigoid (MMP) that developed shortly after a diphtheria tetanus vaccination is described, with a revi

70 The development of acute MMP shortly after a diphtheria tetanus vaccination may have been serendipito

71 isters and erosions 2 days after receiving a diphtheria tetanus vaccination.

72 among those who had only received 1 dose of Diphtheria Tetanus whole cell Pertussis (DTwP).

73 Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DT

74 vaccines (7-valent pneumococcal and combined diphtheria, tetanus, acellular pertussis, inactivated po

75 nited States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vacc

76 the 7- to 10-year-old age group despite high diphtheria, tetanus, and acellular pertussis vaccine (DT

77 es analysis to examine trends in coverage of diphtheria, tetanus, and pertussis (DTP) vaccination acr

78 with the third dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was >

79 children who had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly

80 ) with a primary course only (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] comme

81 related risk estimates, and country-specific diphtheria, tetanus, and pertussus vaccination coverage

82 alongside pentavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis

83 hemagglutinin (FHA), fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were c

84 ere to receive OPV with pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae t

85 of five infant vaccines: polio, pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and H

86 Plasma IgG levels specific for diphtheria, tetanus, pertussis, measles, rubella, and Ha

87 ion schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus i

88 tor: 10% annual improvement in third dose of diphtheria- tetanus-pertussis-containing vaccine (DTP3)

89 is vaccine has been included in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivat

90 ns of an immuno-agent along with a pertussis-diphtheria-tetanus triple vaccine for autoimmune CP/CPPS

91 d in England, 1 year after the program using diphtheria-tetanus-5-component acellular pertussis-inact

92 hypothesis that delay in vaccines containing diphtheria-tetanus-acellular pertussis (DTaP) is associa

93 h 15 months who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the en

94 o adolescent cohorts that received different diphtheria-tetanus-acellular pertussis vaccines (DTaP) d

95 mmunization: combination diphtheria vaccine (diphtheria-tetanus-acellular pertussis-inactivated polio

96 ts in the consistent limb group received the diphtheria-tetanus-acellular pertussis-inactived polio-H

97 nfants presenting for the second dose of the diphtheria-tetanus-pertussis vaccination (given at 8-10

98 ate-reported coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-

99 d through the routine immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2

100 Programme of Immunisation (eg, BCG, measles, diphtheria-tetanus-pertussis, and three doses of polio)

101 d estimates of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) a

102 inly attributable to the vaccination against diphtheria-tetanus-pertussis-poliomyelitis (OR = 1.5) an

103 infections and death, as described following diphtheria-tetanus-whole cell pertussis (DTP) vaccinatio

104 ugars (OAg) of LPS to the nontoxic mutant of diphtheria toxin (CRM(197)).

105 Selective ablation of mitotic neurons using diphtheria toxin (DT) and a retrovirus vector encoding D

106 r 2 (eEF2) is the target of ADP ribosylating diphtheria toxin (DT) and Pseudomonas exotoxin A (PE).

107 tively sensitive to exogenously administered diphtheria toxin (DT) by targeted expression of the diph

108 In adult wild-type mice, administration of diphtheria toxin (DT) caused no significant hair cell lo

109 However, diphtheria toxin (DT) crosses the blood-brain barrier, w

110 We have employed a hormone-inducible diphtheria toxin (DT) expression system in Saccharomyces

111 y timed local (subconjunctival) injection of diphtheria toxin (DT) into mice that express high-affini

112 We generated mice in which administration of diphtheria toxin (DT) led to specific ablation of PYY-ex

113 We inserted diphtheria toxin (DT) receptor (DTR) cDNA into the 3' UT

114 a gene knock-in strategy inserting the human diphtheria toxin (DT) receptor (DTR) into the endogenous

115 Hair cells express the human diphtheria toxin (DT) receptor behind the Pou4f3 promote

116 to the splenic marginal zone of naive CD11b-diphtheria toxin (DT) receptor bone marrow-chimeric mice

117 we used the DEREG mouse, which expresses the diphtheria toxin (DT) receptor under control of the Treg

118 ned CBA/CaJ male mice, engineered to express diphtheria toxin (DT) receptors in hair cells, by system

119 Administration of diphtheria toxin (DT) to these mice resulted in nearly c

120 Tg) mice but not in CLEC4C-DTR-Tg mice after diphtheria toxin (DT) treatment.

121 ic tyrosinase promoter, under the control of diphtheria toxin (DT), we eliminated and/or halted diffe

122 glycemia after induction of a more complete, diphtheria toxin (DT)-induced beta-cell loss, a situatio

123 cTECs sensitive to the cytotoxic effects of diphtheria toxin (DT).

124 ecifically ablated from adult mice using the diphtheria toxin (DT)/DT-receptor system and the connexi

125 ynthetic antigen was conjugated to a mutated diphtheria toxin (DT, CRM197) with different copy number

126 ed with CRE-dependent AAV vectors expressing diphtheria toxin (DTA) to selectively ablate FC SST neur

127 Previous diphtheria toxin (DTA)-mediated ablation studies showed

128 addition to Stx, the phage-encoded exotoxin, diphtheria toxin (Dtx) expressed by Corynebacterium diph

129 in conjunction with mice expressing GFP and diphtheria toxin (DTx) receptor (DTR) under control of t

130 the lethal factor amino-terminal domain and diphtheria toxin A chain expedited translocation.

131 on, utilizing temporally controlled targeted diphtheria toxin A expression, results in failure of neu

132 Interestingly, neutropenic lysozyme 2-diphtheria toxin A mice exhibited striking EG and amplif

133 s) via Cre-dependent viral expression of the diphtheria toxin A subunit (DT-A) in hemiparkinsonian tr

134 in mice for 25 d via neuronal expression of diphtheria toxin A-chain, producing both a neuroinflamma

135 be specifically depleted from the brain upon diphtheria toxin administration.

136 splantation carrying a conditional allele of diphtheria toxin alpha subunit and cell-specific express

137 utively ablated because of expression of the diphtheria toxin alpha subunit within developing DCs.

138 We found that diphtheria toxin and its nontoxic mutant, called CRM197,

139 hMAb binds to the receptor-binding domain of diphtheria toxin and physically blocks the toxin from bi

140 teins that include the key virulence factors diphtheria toxin and the adhesive pili.

141 as their bovine serum albumin or recombinant diphtheria toxin conjugates.

142 etane grafting of the genetically detoxified diphtheria toxin CRM197 improves significantly the immun

143 Injection of diphtheria toxin deleted YFP(+) cells from Foxl1-Cre;Ros

144 Some mice were given injections of diphtheria toxin during the recovery phase to delete Fox

145 odon in the Rosa26(DTA/+) allele and induces diphtheria toxin fragment A (DTA) expression.

146 specific CreER allele to drive expression of diphtheria toxin fragment A (DTA).

147 Denileukin diftitox (DD), a diphtheria toxin fragment IL-2 fusion protein, is though

148 inducible Caspase-8 protein and an inducible diphtheria toxin gene, results in new neurons.

149 transformation method by the introduction of diphtheria toxin genes into the transformation vector as

150 d potent human neutralizing antibody against diphtheria toxin holds promise as a potential therapeuti

151 family includes ADP-ribosyltransferases with diphtheria toxin homology (ARTD).

152 The 18 human ADP-ribose transferases with diphtheria toxin homology include ARTD1/PARP1, a cancer

153 Transient expression of diphtheria toxin in beta cells of old mice resulted in i

154 ique hMAbs were tested for neutralization of diphtheria toxin in in vitro cytotoxicity assays with a

155 Five days after administering diphtheria toxin in these adult mice, changes were obser

156 In these albumin-deficient rats, exposure to diphtheria toxin induced an increase in albumin GSC and

157 use, a model of hyperglycemia resulting from diphtheria toxin induced beta cell ablation.

158 model, PMN(DTR) mice, in which injection of diphtheria toxin induces selective neutrophil ablation.

159 Within 2 weeks of diphtheria toxin injection, heterozygous Pmch(DTR/+) mic

160 nd that limited podocyte renewal occurs in a diphtheria toxin model of acute podocyte ablation.

161 and covalently linked to recombinant CRM197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197.

162 hesized and attached via a chain linker to a diphtheria toxin mutant carrier protein.

163 calizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds

164 lls was assessed by selective depletion with diphtheria toxin or depleting anti-CD20 monoclonal antib

165 Screens for sensitivity to a cholera-diphtheria toxin provide broad insights into the mechani

166 onate (sLC), inducible depletion using CD11b diphtheria toxin receptor (CD11b DTR) transgenic mice, a

167 pletion of this population in CD11B promoter-diphtheria toxin receptor (CD11B-DTR) transgenic mice ca

168 onstituted with bone marrow cells from CD11c-diphtheria toxin receptor (CD11c-DTR) and CCR5(-/-) or C

169 Cs from LNs based on their expression of the diphtheria toxin receptor (DTR) directed by the gene enc

170 Many such models rely on transgenic diphtheria toxin receptor (DTR) expression driven by DC-

171 e adult mouse utricle by inserting the human diphtheria toxin receptor (DTR) gene into the Pou4f3 gen

172 tance, using B6.Foxp3(DTR) mice that express diphtheria toxin receptor (DTR) in Foxp3(+) cells.

173 In these mice, the diphtheria toxin receptor (DTR) is expressed under contr

174 Conditional expression of diphtheria toxin receptor (DTR) is widely used for tissu

175 in vivo, we targeted expression of the human diphtheria toxin receptor (DTR) to the gene for MCH (Pmc

176 used several murine models, including BDCA-2-diphtheria toxin receptor (DTR) transgenic and IFN-alpha

177 s were eliminated in newly generated SiglecH-diphtheria toxin receptor (DTR)-transgenic (Tg) mice but

178 Expression of the human diphtheria toxin receptor (hDTR) gene under the regulato

179 el transgenic mouse model in which the human diphtheria toxin receptor (huDTR) is selectively express

180 m1cre mice were bred to homozygous inducible diphtheria toxin receptor (iDTR) mice to generate mice e

181 using the human diphtheria receptor system (diphtheria toxin receptor [DTR]) expressed in Lysmd1-cre

182 cendants (Foxl1-Cre;Rosa(YFP/iDTR)-inducible diphtheria toxin receptor [iDTR] mice).

183 By using B6/Langerin-diphtheria toxin receptor chimeric mice and LC ablation,

184 We generated mice that express the diphtheria toxin receptor exclusively in podocytes, allo

185 Using CX3CR1(CreER) to drive diphtheria toxin receptor expression in microglia, we fo

186 To test this hypothesis, we used a diphtheria toxin receptor expression system to selective

187 nondiabetic mice conditionally expressing a diphtheria toxin receptor in mural cells.

188 ria toxin (DT) by targeted expression of the diphtheria toxin receptor in oligodendrocytes.

189 Using Langerin-diphtheria toxin receptor mice and established mouse mod

190 ished hepatic metastases in transgenic CD11b-diphtheria toxin receptor mice by intrasplenic injection

191 n, in either Mac1-deficient mice or in CD11b-diphtheria toxin receptor mice in which CD11b-positive c

192 etion of Treg during MCMV infection in Foxp3-diphtheria toxin receptor mice or in wild-type mice reca

193 g monocytes only in CCR2 promoter-controlled diphtheria toxin receptor mice, whereas neutrophil numbe

194 otein (EGFP) knock-in mice and Langerin-EGFP-diphtheria toxin receptor mice--three dimensional rotati

195 CD11b/Gr1(mid) subset in a transgenic CD11b-diphtheria toxin receptor mouse model markedly reduced t

196 e have generated a transgenic strain, Clec9A-diphtheria toxin receptor that allows us to ablate in vi

197 Therefore, the diphtheria toxin receptor transgene was specifically exp

198 phtheria toxin treatment of sensitized CD11c-diphtheria toxin receptor transgenic mice to deplete CD1

199 We used CD11b-diphtheria toxin receptor transgenic mice to transiently

200 t C57BL/6-DEREG mice expressing a transgenic diphtheria toxin receptor under the Foxp3 promoter, tran

201 se line, using the Cre/loxP system, in which diphtheria toxin receptor was selectively expressed in m

202 Foxp3-GFP-DTR (human diphtheria toxin receptor) C57BL/6 mice allow eliminatio

203 tein, cluster of differentiation 11c (CD11c)/diphtheria toxin receptor, and IL-17 receptor A(-/-) mic

204 We developed a diphtheria toxin receptor-based strategy to selectively

205 induced responses in CD11c promoter-directed diphtheria toxin receptor-expressing mice that were depl

206 r macrophages and in CD11b promoter-directed diphtheria toxin receptor-expressing mice that were depl

207 We used immunophenotyping techniques and diphtheria toxin receptor-expressing, chemokine receptor

208 the number of macrophages in mice following diphtheria toxin receptor-mediated cell ablation of panc

209 ith type II AEC-restricted expression of the diphtheria toxin receptor.

210 mice expressing the CCR2 promoter-controlled diphtheria toxin receptor.

211 y podocyte-specific transgenic expression of diphtheria toxin receptor.

212 d a combinatorial viral technique to express diphtheria toxin receptors in specific neuron population

213 a membrane-anchored metal ion permease and a diphtheria toxin repressor (DtxR)-like transcriptional r

214 Diphtheria toxin robustly depleted circulating monocytes

215 enzymatically inactive and nontoxic form of diphtheria toxin that contains a single amino acid subst

216 plasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via

217 izures were frequent, mice were treated with diphtheria toxin to ablate peri-insult generated newborn

218 on of CD11c(high) cells by administration of diphtheria toxin to CD11c.DOG mice.

219 ol of intracerebroventricular application of diphtheria toxin to efficiently ablate hypothalamic cell

220 We induced autonomous expression of diphtheria toxin to kill articular surface chondrocytes

221 ontributes to lung fibrosis, we administered diphtheria toxin to transgenic mice with type II AEC-res

222 switching in several systems, including the diphtheria toxin translocation (T) domain, which is resp

223 cdB and the well-characterized alpha-helical diphtheria toxin translocation domain provide insights i

224 A single systemic diphtheria toxin treatment 2 d before HSV-1 corneal infe

225 In this study, we used diphtheria toxin treatment of sensitized CD11c-diphtheri

226 In chimeric CD11c-DTR mice, diphtheria toxin treatment results in enhanced neutrophi

227 d to those conjugated to tetanus (TT) or the diphtheria toxin variant, CRM.

228 X-expressing neurons after administration of diphtheria toxin while leaving the neural precursor pool

229 ination of Foxp3+ Treg by treatment with Dx (diphtheria toxin).

230 ectories of the conformational transition of diphtheria toxin, a particularly challenging example, sh

231 detrimental effects of anthrax lethal toxin, diphtheria toxin, cholera toxin, Pseudomonas aeruginosa

232 lectively deplete human stromal cells (using diphtheria toxin, DT) without affecting mouse cancer cel

233 Diphthamide, the target of diphtheria toxin, is a post-translationally modified his

234 Diphthamide, the target of diphtheria toxin, is a unique posttranslational modifica

235 vidity of immunoglobulin (Ig) G specific for diphtheria toxin, pertussis toxin, filamentous hemagglut

236 Its name refers to the target function for diphtheria toxin, the disease-causing agent that, throug

237 Thus, in contrast to diphtheria toxin, the formation of a membrane-competent

238 e, using doxycycline-inducible expression of diphtheria toxin, triggers a significant compensatory pr

239 x (DD), a fusion protein comprising IL-2 and diphtheria toxin, was initially expected to enhance anti

240 ecifically ablated through administration of diphtheria toxin, we demonstrate that natural Tregs are

241 sing Tregs that can be depleted in vivo with diphtheria toxin, we show that injected cells are requir

242 al switching is essential for functioning of diphtheria toxin, which undergoes a membrane insertion/t

243 ono-ADP-ribosyltransferase proteins, such as diphtheria toxin, with the exception of a unique loop th

244 e used a transgenic mouse system that allows diphtheria toxin-based depletion of pericytes.

245 fically depleted CD4(+)Foxp3(+) T cells in a diphtheria toxin-dependent manner.

246 esponse and type 2 diabetes mellitus (T2DM), diphtheria toxin-expressing (DT) mice that specifically

247 ischemia/reperfusion (I/R) injury or a novel diphtheria toxin-induced (DT-induced) model of selective

248 state was perturbed by coronary ligation or diphtheria toxin-induced macrophage depletion in CD11b(D

249 microglia exert beneficial effects during a diphtheria toxin-induced neuronal lesion, but impede rec

250 ied as a potent but unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3).

251 The diphtheria toxin-like ADP-ribosyltransferases (ARTDs) ar

252 Diphtheria toxin-mediated ablation of lysozyme M-positiv

253 o acutely and selectively eliminate them via diphtheria toxin-mediated ablation.

254 answer this question, we used Cre-dependent, diphtheria toxin-mediated cell ablation to selectively r

255 Using a progressive, time-controllable, diphtheria toxin-mediated cell ablation/dysfunction tech

256 Using diphtheria toxin-mediated depletion models in mice, we s

257 Importantly, diphtheria toxin-mediated depletion of IL-7-producing st

258 Diphtheria toxin-mediated selective depletion of MCs or

259 Diphtheria toxin-mediated, acute ablation of hypothalami

260 ma cells before depleting myeloid cells with diphtheria toxin.

261 variety of recombinant protein fragments of diphtheria toxin.

262 xpressing cells can be depleted by injecting diphtheria toxin.

263 IL-2 protein and as toxophore the truncated diphtheria toxin.

264 tly but selectively depleted by injection of diphtheria toxin.

265 y intracerebroventricular (ICV) injection of diphtheria toxin.

266 cific ablation of podocytes by administering diphtheria toxin.

267 nsive islet infiltration upon treatment with diphtheria toxin.

268 immunity, only if Tregs were depleted using diphtheria toxin.

269 ogenic insult using a conditional, inducible diphtheria-toxin receptor expression strategy in mice.

270 Diphtheria-toxin receptor expression was induced among g

271 nction, we eliminated DCS cells by using the diphtheria-toxin receptor gene knocked into the murine R

272 ataxin-3-orexin, and doxycycline-controlled-diphtheria-toxin-A-orexin.

273 ), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially

274 onjugated to an immunogenic carrier protein, diphtheria toxoid (DT), and formulated in a nanoparticul

275 nd did not affect infant immune responses to diphtheria toxoid and pneumococcal vaccination.

276 in the infants and their immune response to diphtheria toxoid and pneumococcal vaccination.

277 nt meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT).

278 ere then conjugated with the carrier protein diphtheria toxoid cross-reactive material (CRM) 197 (DT)

279 otein, including keyhole limpet hemocyanion, diphtheria toxoid cross-reactive material (CRM) 197 (DT)

280 However, S2 conjugated to diphtheria toxoid is highly immunogenic and induces Abs

281 ings, which showed that protection by the J8-diphtheria toxoid vaccine is Ab-mediated and suggest tha

282 al immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin

283 recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap

284 single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine).

285 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was

286 (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and

287 ted a panel of diverse hMAbs that recognized diphtheria toxoid, as well as a variety of recombinant p

288 ning only 12 aa from GAS, when conjugated to diphtheria toxoid, has been shown to protect mice agains

289 s documented; (6) neonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertuss

290 Control and Prevention recommend tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccin

291 us, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis vaccines.

292 ached to protein carriers such as tetanus or diphtheria toxoids.

293 number of human diseases, including cholera, diphtheria, traveler's diarrhea, and whooping cough.

294 organism commonly associated with cutaneous diphtheria, usually seen as an imported tropical disease

295 acterium diphtheriae, the etiologic agent of diphtheria, utilizes heme and hemoglobin (Hb) as iron so

296 ization schedules recommend that tetanus and diphtheria vaccination be performed every 10 years.

297 s received routine immunization: combination diphtheria vaccine (diphtheria-tetanus-acellular pertuss

298 acellular pertussis, inactivated polio, and diphtheria vaccines at 12 to 24 months of age.

299 11-17 years), whereas antibody responses to diphtheria were more long-lived and declined with an est

300 Respiratory diphtheria with the absence of a pharyngeal membrane was